2017
Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer Surgery
Salazar MC, Rosen JE, Wang Z, Arnold BN, Thomas DC, Herbst RS, Kim AW, Detterbeck FC, Blasberg JD, Boffa DJ. Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer Surgery. JAMA Oncology 2017, 3: 610-619. PMID: 28056112, PMCID: PMC5824207, DOI: 10.1001/jamaoncol.2016.5829.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantDrug Administration ScheduleFemaleHumansLung NeoplasmsMaleMiddle AgedNeoplasm GradingNeoplasm StagingPneumonectomyPostoperative PeriodProportional Hazards ModelsRetrospective StudiesTreatment OutcomeUnited StatesConceptsLung cancer surgeryCell lung cancer resectionAdjuvant chemotherapyLung cancer resectionNational Cancer DatabaseCell lung cancerLower mortality riskCancer surgeryCox modelCancer resectionLung cancerCancer DatabaseMortality riskCell lung cancer surgeryHospital-based tumor registryIncident lung cancer casesPostoperative multiagent chemotherapyInitiation of chemotherapyTreatment-naive patientsPropensity-matched pairsRetrospective observational studyLymph node metastasisLung cancer casesChemotherapy initiationPostoperative chemotherapy
2016
Adjuvant Chemotherapy for T3 Non–Small Cell Lung Cancer with Additional Tumor Nodules in the Same Lobe
Salazar MC, Rosen JE, Arnold BN, Thomas DC, Kim AW, Detterbeck FC, Blasberg JD, Boffa DJ. Adjuvant Chemotherapy for T3 Non–Small Cell Lung Cancer with Additional Tumor Nodules in the Same Lobe. Journal Of Thoracic Oncology 2016, 11: 1090-1100. PMID: 27013407, DOI: 10.1016/j.jtho.2016.03.009.Peer-Reviewed Original ResearchConceptsAdditional tumor nodulesAdjuvant chemotherapyT3 tumorsSame lobeTumor nodulesPostoperative chemotherapyOverall survivalSurgical resectionSurvival advantageNon-small cell lung cancerNational Cancer Data BaseNon-small cell lungAdditional pulmonary nodulesAdjuvant chemotherapy subgroupSurvival of patientsCell lung cancerSeparate tumor nodulesChemotherapy subgroupPrimary outcomeCell lungLung cancerChemotherapyCox modelRelative survivalPatients
2014
Now or Later: Evaluating the Importance of Chemotherapy Timing in Resectable Stage III (N2) Lung Cancer in the National Cancer Database
Boffa DJ, Hancock JG, Yao X, Goldberg S, Rosen JE, Kim AW, Moreno A, Detterbeck FC. Now or Later: Evaluating the Importance of Chemotherapy Timing in Resectable Stage III (N2) Lung Cancer in the National Cancer Database. The Annals Of Thoracic Surgery 2014, 99: 200-208. PMID: 25440272, DOI: 10.1016/j.athoracsur.2014.08.040.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerNational Cancer DatabaseStage III non-small cell lung cancerPreoperative chemotherapyPostoperative chemotherapyLung cancerCancer DatabaseIII-N2 non-small cell lung cancerStage III lung cancerStage III NSCLC patientsTiming of chemotherapyCell lung cancerCox proportional hazardsSeparate Cox modelsNSCLC patientsChemotherapy resultsChemotherapy timingAdjusted comparisonsChemotherapy approachesChemotherapyCox modelProportional hazardsPatientsTumor attributesCStage